Obermatt
See Similar Stocks →

argenx

BRU:ARGX · NL0010832176
BiotechnologyLarge

360° View

98
Price/Sales31
Price/Earnings11
Price/Book18
Dividend Yield97
Revenue Growth79
Profit Growth100
Capital Growth7
TSR 52w71
Leverage90
Liquidity98
Refinancing80
Combined96
Analyst Opinions55
Pro Holdings85
Opinion Changes25
Market Pulse99

Profile

CountryNetherlands
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeENXTBR
Founded2008
Websiteargenx.com
ISINNL0010832176
Last UpdateApr 2, 2026
Index & Theme
OphthalmologyRheumatologyHealth DiagnosticsImmunologyInflammationOncologyCentral Nervous SystemNeurologyChronic Diseases

Description

argenx SE (argenx) operates as a commercial-stage, global, fully integrated biopharma company. Throughout 2025, the company continued to deliver meaningful impact for patients globally, reaching more than 19,000 patients across three indications (gM…

Analysis

argenx's 360° View rank of 98 places it among the strongest overall — better than 98% of its true peers.

It's growing solidly (74) and reasonably valued (53). On safety it is very well financed (98), and the market shows strongly positive sentiment (91). Taken together, its Combined rank of 96 reads as among the strongest overall.

360° rank · history

1007550250
98
2026

All-time high

98

Mar 2026

All-time low

96

Feb 2026

Average rank

97

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
31
—
—
—
Price/Earnings
11
—
—
—
Price/Book
18
—
—
—
Dividend Yield
97
—
—
—
Value (overall)
53
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare argenx with its peers
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Kiniksa Pharmaceuticals
NSQ:KNSA
99
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Mereo BioPharma Group
NAQ:MREO
51
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Alvotech
NMQ:ALVO
18
CountryLuxembourg
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Roivant Sciences
NSQ:ROIV
47
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →